Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
about
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesDepletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptidesSimultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure.Natriuretic Peptide testing in primary careBrain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentHuman hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.Nesiritide in acute decompensated heart failure: current status and future perspectivesSecretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure.Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy.Prognostic value of circulating chromogranin A levels in acute coronary syndromesThe cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failureMolecular and physiological effects of nesiritideB-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity.Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department.Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside.Natriuretic peptides in the diagnosis and management of chronic heart failure.Molecular forms of natriuretic peptides in heart failure and their implications.Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction.B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications.Practical application of natriuretic peptides in paediatric cardiology.B-type natriuretic peptides in heart failure: update on clinical applications and limitations.Diverse molecular forms of plasma B-type natriuretic peptide in heart failure.The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.MS-based approaches to unravel the molecular complexity of proprotein-derived biomarkers and support their quantification: the examples of B-type natriuretic peptide and apelin peptides.Natriuretic peptide-guided therapy: further research required for still-unresolved issues.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.Does B-type natriuretic peptide or its gene polymorphism predict patient outcome after coronary artery bypass graft surgery?Clinical value of a competitive NT-proBNP enzyme immunoassay compared to the Roche NT-proBNP platform.Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma.Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status.Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs.Associates of an elevated natriuretic peptide level in stable heart failure patients: implications for targeted management.Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
P2860
Q28282265-6D191709-B08B-43EE-9A55-0C9C82C2057DQ28533555-6AA67E1E-321F-4112-9285-EFD2834E8F40Q33526958-F904FFB8-5C53-43FE-B6B9-0B6F7ED4D97CQ33572286-90A4DA56-CB8B-46FA-8B8C-B4BF347187CCQ33573360-A0D318C7-3ABE-4DBE-8ACF-CF77A0919431Q33698918-B996A7EA-1DCB-40B6-B8F1-CD6B7E91DA0CQ33878162-9823217C-BB89-4732-8D53-DDFACA0594E7Q33994980-7EF95CB8-4151-4988-8E75-16E1C19028EFQ36868077-EE038978-D691-4F8D-9DA3-19D4607EB373Q37090512-EA98FC72-95D0-4045-B91E-657AD7ABFEBFQ37091016-D9B2D0F4-49C9-4CBB-AD35-4124191AE436Q37217345-F0E6B88A-272E-416A-8854-B254F498C367Q37217952-C5FD3AA8-E528-4305-9BA2-6F8F0C9AAD77Q37229555-A5A99A30-1721-451F-AF96-A1979BFF2570Q37425253-1996D02C-B03B-4BC5-8F12-4A4544D14322Q37447544-62622CC9-9756-465E-BDBE-257C306743A4Q37487209-E945376C-DEDC-47DC-A3C8-37D3A850E3EFQ37591134-9EBAE078-86A5-4F50-B4F4-37A09B0F3B81Q37734430-72622D6D-8A57-44F3-B92E-16F460E25D13Q37748955-CD2E5FE3-147F-48F0-BA59-C9ED6BE76E7FQ37755062-8C11E0AE-08DD-42B5-93DD-9D0C0C4C75E9Q37845737-8DA3C9F6-5F86-47F0-8D3E-62F7771C004FQ38063118-E89F0B28-02DC-4D30-AF56-1A7A5D9D7771Q38065253-5814C82A-DA7C-4CF1-9C7D-500E20292B26Q38099221-3DB301CC-EDA2-498A-9596-B015EB66698AQ38261513-050D746C-50C9-4F30-848F-B13B6F1F8793Q42426682-B47A696E-A9FE-461A-86CC-05D54B998E7EQ48460261-6BF6B48B-8B3F-49D9-9F31-33EAA367F512Q48521740-4A21E008-C0B8-4826-9F48-8D1B95A62AC6Q48942319-9C7AA3E9-6FFF-4C29-A0F9-DCC8A0B4353CQ49179704-B2852E1D-C561-426E-BCBD-92AF191FC592Q55533888-9EEE9734-C8BD-4705-B73F-D2CA20099EDAQ57097937-0A281903-FFC5-4A63-9C6A-98DACF0079D9
P2860
Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Alternate circulating pro-B-ty ...... rms in the general population.
@ast
Alternate circulating pro-B-ty ...... rms in the general population.
@en
type
label
Alternate circulating pro-B-ty ...... rms in the general population.
@ast
Alternate circulating pro-B-ty ...... rms in the general population.
@en
prefLabel
Alternate circulating pro-B-ty ...... rms in the general population.
@ast
Alternate circulating pro-B-ty ...... rms in the general population.
@en
P2093
P1476
Alternate circulating pro-B-ty ...... rms in the general population.
@en
P2093
Carolyn S P Lam
John C Burnett
Lisa Costello-Boerrigter
Margaret M Redfield
Richard J Rodeheffer
P304
P356
10.1016/J.JACC.2006.12.024
P407
P577
2007-03-06T00:00:00Z